Monte Rosa Therapeutics Inc

GLUENASDAQ · USD
9.07USD0.00 (-0.99%)
155

Monte Rosa Therapeutics Inc (GLUE) Implied Volatility Current

GLUE's 30 day implied volatility is 130.77%, with an IV Rank of 66.67%. This is an average IV Rank versus the past year, meaning Monte Rosa Therapeutics Inc options are fairly priced and currently offer no clear edge to buyers or sellers. GLUE's 30 day historical volatility sits at 58.75%, which means implied volatility is running 72.02 points above historical volatility, as of Nov 17, 2026.

Read more

Tracking GLUE implied volatility helps you spot when Monte Rosa Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When GLUE IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor GLUE implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking GLUE IV rank helps you see whether GLUE's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.

Implied Volatility

IV Rank
66.67%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)130.77%

IV Rank66.67%

Historical Volatility (30d)58.75%

IV Minus HV+72.02%

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →